Biohaven (BHVN) is up ~8% in Thursday trading after reporting phase 1 data on a combination of its Trop2 antibody drug conjugate BHV-1510 with Regeneron Pharmaceuticals’ (REGN) Libtayo (cemiplimab) across several tumor types.
Enrolled patients had prior treatment, mostly with PD-L1
